ClinicalTrials.gg
CompletedNCT04753879Updated Nov 4, 2026Results posted

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

A Phase 2 interventional study of Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know · 18 judgments · 6 readings being read again

Updated Nov 4, 2026Now CompletedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing pembrolizumab in Pancreatic Neoplasms — 5 open to participants now, 9 under way, 1 of them phase 3. pembrolizumab · Pancreatic Neoplasms.

Enrollment
11th of 20
36 · median 38
Started
2021
with 3 others
Phase 2
12 of 20
3 open now
Registered
13th of 20
by date

Among the 20 studies testing pembrolizumab in Pancreatic Neoplasms, this one is the 11th largest by enrollment, is one of 4 that started in 2021, is one of 12 in phase 2, and was the 13th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

5 of the 20 studies testing pembrolizumab in Pancreatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing pembrolizumab in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.

03

Conditions studied

  • Metastatic Pancreatic Cancer

Keywords

  • PARP
  • Gemcitabine
  • Nab-paclitaxel
  • Capecitabine
  • Cisplatin
  • Irinotecan
  • Olaparib
  • Pembrolizumab
  • Immunotherapy
  • PD-L1 (receptor blocking antibody)
  • Anti-PD-L1
  • Monoclonal Antibodies
  • Metastatic pancreatic cancer
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and willingness to sign a written document.
  • Age ≥18 years.
  • (ECOG) performance status 0 or 1
  • Have or cytologically-proven ductal pancreatic cancer.
  • Patients must not have received prior treatment for pancreatic cancer.
  • Have based on 1.1.
  • Willing to have to a tumor .
  • Patients must have adequate organ and marrow function defined by study - specified laboratory tests.
  • Women of must have a negative pregnancy test and follow guidelines as defined per protocol.
  • Men must use acceptable form of birth control while on study.
  • Participant understands the study regimen, its requirements, risks and discomforts, competent to report AE, understand the drug dosing schedule and use of medications to control AE.

Exclusion criteria

Exclusion Criteria:

  • Patients who will be considered for surgery are ineligible.
  • Had chemotherapy within 5 years prior to study treatment.
  • Have received any drugs within 28 days prior to study treatment.
  • Had surgery within 28 days of dosing of investigational agent.
  • Has history of central nervous system (CNS) and/or carcinomatous meningitis.
  • Require any antineoplastic therapy.
  • Has received prior therapy with an , anti-PD-L1, or anti PD L2 agent.
  • Has received prior therapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, or PARP inhibitor.
  • reaction to any monoclonal antibody.
  • Is taking a moderate or strong inhibitor.
  • Has uncontrolled acute or chronic medical illness.
  • Has known additional that is progressing and requires active treatment.
  • Has received radiotherapy for pancreatic cancer.
  • Have received any or live-attenuated, any allergen hyposensitization therapy, growth factors or major surgery within 30 days prior to study treatment.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has active disease.
  • Has an active known or suspected autoimmune disease or is receiving chronic systemic therapy within 7 days prior to the first dose of study drug.
  • Prior tissue or organ allograft or bone marrow transplantation.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Requirement for daily supplemental oxygen.
  • Patients with a history of (non-infectious) pneumonitis/interstitial lung disease that requires steroids.
  • Subject with wound.
  • Has a confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to .
  • Infection with .
  • Has active (defined as Hepatitis B surface antigen [HBsAg] reactive) or virus (defined as hepatitis C virus (HCV) RNA [qualitative] is detected) infection. Patients who are Hepatitis C antibody positive and viral load negative will be permitted to enroll.
  • Has uncontrolled infection.
  • Unwilling to have blood drawn.
  • Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial.
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    GAX-CI Chemotherapy with Pembrolizumab and Olaparib

    The treatment period will consist of a chemotherapy phase with GAX-CI (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan) followed by a maintenance phase with pembrolizumab and olaparib. The chemotherapy phase will consist of 6 cycles of GAX-CI. Post-GAX-CI treatment, patients will receive pembrolizumab and olaparib. Maintenance phase treatment may continue up to a maximum of 2 years. Patients who had stable disease or better post-GAX-CI treatment and develop clinical or radiographic progressive disease following initiation of maintenance therapy, or those who become intolerant of treatment with either pembrolizumab or olaparib, may be retreated with GAX-CI if the PI deems that the patient will derive meaningful clinical benefit.

    Drug: Nab-paclitaxel · Drug: Gemcitabine · Drug: Cisplatin · Drug: Irinotecan · Drug: Capecitabine · Drug: Pembrolizumab · Drug: Olaparib

Interventions

  • DrugAlbumin-Bound PaclitaxelBeing read again: the record changed after it was read.Studies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nab-paclitaxel (80 mg/m\^2) will be administered IV on Day 1 and Day 15 of each Cycle for up to 6 Cycles during the GAX-CI Chemotherapy Phase. Each Cycle is 28 days.

    Also known as: Abraxane

  • Gemcitabine (500mg/m\^2) will be administered IV on Day 1 and Day 15 of each Cycle for up to 6 Cycles during the GAX-CI Chemotherapy Phase. Each Cycle is 28 days

    Also known as: Gemzar

  • Cisplatin (20mg/m\^2) will be administered IV on Day 1 and Day 15 of each Cycle for up to 6 Cycles during the GAX-CI Chemotherapy Phase. Each Cycle is 28 days

  • Irinotecan (20 mg/m\^2) will be administered IV on Day 1 and Day 15 of each Cycle for up to 6 Cycles during the GAX-CI Chemotherapy Phase. Each Cycle is 28 days

  • Capecitabine (500 mg) will be administered orally twice a day on Days 1-7 and 15-21 of each Cycle for up to 6 Cycles during the GAX-CI Chemotherapy Phase. Each Cycle is 28 days

    Also known as: Xeloda

  • Pembrolizumab (400 mg) will be administered IV on day 1 every other Cycle (every 6 weeks) during the Maintenance Phase for up to 2 years. Each Cycle is 28 days.

    Also known as: MK-3475; Keytruda

  • Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each Cycle during the Maintenance Phase for up to 2 years. Each Cycle is 28 days.

    Also known as: Lynparza

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Rate at 6 Months

    The 6-month PFS rate is defined as the Kaplan-Meier estimate of the proportion of patients without disease progression or death at 6 months from the date of first dose of maintenance therapy (pembrolizumab and olaparib) after disease stabilization (SD, PR, or CR per RECIST 1.1 criteria) with 6 cycles of GAX-CI. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.

    Time frame: 6 Months

Secondary outcomes

  1. Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities

    When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.

    Time frame: Up to 34 months

07

Results

Posted Nov 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneGAX-CI Chemotherapy With Pembrolizumab and Olaparib
Started36
Completed19
Not completed17

Outcome measures

PrimaryProgression-free Survival (PFS) Rate at 6 Months

The 6-month PFS rate is defined as the Kaplan-Meier estimate of the proportion of patients without disease progression or death at 6 months from the date of first dose of maintenance therapy (pembrolizumab and olaparib) after disease stabilization (SD, PR, or CR per RECIST 1.1 criteria) with 6 cycles of GAX-CI. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.

Time frame:
6 Months
Reported as:
Number · Percent
Progression-free Survival (PFS) Rate at 6 Months
PercentGAX-CI Chemotherapy With Pembrolizumab and Olaparib
Progression-free Survival (PFS) Rate at 6 Months21.05 (8.81 to 50.29)
SecondaryNumber of Participants Experiencing Grade 3 or Above Drug-related Toxicities

When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.

Time frame:
Up to 34 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities
ParticipantsGAX-CI Chemotherapy With Pembrolizumab and Olaparib
Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities13

Adverse events

Collected over Serious and Other (Not Including Serious) Adverse Events were evaluated for up to 34 months. All-cause mortality was evaluated for up to 41 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GAX-CI Chemotherapy With Pembrolizumab and Olaparib30/36 (83.3%)22/36 (61.1%)36/36 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventGAX-CI Chemotherapy With Pembrolizumab and Olaparib
Disease ProgressionGeneral disorders6/36
SepsisInfections and infestations4/36
Thromboembolic eventVascular disorders4/36
AnemiaBlood and lymphatic system disorders3/36
Abdominal painGastrointestinal disorders2/36
BacteremiaInfections and infestations2/36
Biliary ObstructionHepatobiliary disorders2/36
Biliary tract infectionInfections and infestations2/36
Cardiac arrestCardiac disorders2/36
HypotensionVascular disorders2/36
Most frequent other events
Showing 10 of 88
Most frequent other events
EventGAX-CI Chemotherapy With Pembrolizumab and Olaparib
FatigueGeneral disorders25/36
Weight lossInvestigations20/36
Abdominal PainGastrointestinal disorders15/36
AlopeciaSkin and subcutaneous tissue disorders15/36
NauseaGastrointestinal disorders15/36
PainGeneral disorders15/36
ConstipationGastrointestinal disorders13/36
DiarrheaGastrointestinal disorders12/36
Edema limbsGeneral disorders12/36
HypomagnesemiaMetabolism and nutrition disorders12/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GAX-CI Chemotherapy With Pembrolizumab and Olaparib
<=18 years0
Between 18 and 65 years15
>=65 years21
Sex: Female, Male
Sex: Female, Male(Participants)GAX-CI Chemotherapy With Pembrolizumab and Olaparib
Female15
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GAX-CI Chemotherapy With Pembrolizumab and Olaparib
Hispanic or Latino0
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GAX-CI Chemotherapy With Pembrolizumab and Olaparib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White32
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)GAX-CI Chemotherapy With Pembrolizumab and Olaparib
United States36
08

Study locations

1 site
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2026, 55 months.

Results were first posted in Nov 2026, 5 months after primary completion.

Of 327 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's 55 months is close to that.

Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → May 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 15, 2021
StartActual
Sep 29, 2021
Primary completionActual
May 7, 2026was Jul 2026
CompletionActual
Jul 1, 2026
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Results
Results posted
posted Nov 4, 2026
Primary completion
Jul 1, 2026→May 7, 2026 (actual)
Nov 4, 2026
Enrollment
38 (estimated)→36 (actual)
Nov 4, 2026
Eligibility
1 inclusion criterion edited, 2 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • RemovedCohort 1 - Subject has stable disease as measured by RECIST 1.1 or iRECIST after 6 cycles of GAX-CI.
  • RemovedCohort 2 - Subject has progressive disease as measured by RECIST 1.1 and iRECIST prior to 6 cycles of GAX-CI.
  • EditedWomanWomen of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
Exclusion criteria
  • EditedWomanWomen who are pregnant or breastfeeding.
Nov 4, 2026
Interventions
Arm changed Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine→GAX-CI Chemotherapy with Pembrolizumab and Olaparib
Nov 4, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedProgression-free Survival (PFS) afterRate at 6 months according to RECIST 1.1 criteria.MonthsTime frame: 6 Months
  • RemovedProgression-free Survival (PFS) after 6 months according to IRECIST criteria.Time frame: 6 months
Nov 4, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of participants experiencing gradeParticipants Experiencing Grade 3 or above drugAbove Drug-related toxicitiesToxicitiesTime frame: 4 years → Up to 34 months
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Jul 1, 2026→May 7, 2026 (now actual)
    Enrollment 38 (estimated)→36 (actual)
    Eligibility 1 inclusion criterion edited, 2 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • RemovedCohort 1 - Subject has stable disease as measured by RECIST 1.1 or iRECIST after 6 cycles of GAX-CI.
    • RemovedCohort 2 - Subject has progressive disease as measured by RECIST 1.1 and iRECIST prior to 6 cycles of GAX-CI.
    • EditedWomanWomen of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
    Exclusion criteria
    • EditedWomanWomen who are pregnant or breastfeeding.
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedProgression-free Survival (PFS) afterRate at 6 months according to RECIST 1.1 criteria.MonthsTime frame: 6 Months
    • RemovedProgression-free Survival (PFS) after 6 months according to IRECIST criteria.Time frame: 6 months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of participants experiencing gradeParticipants Experiencing Grade 3 or above drugAbove Drug-related toxicitiesToxicitiesTime frame: 4 years → Up to 34 months
    Interventions Arm changed Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine→GAX-CI Chemotherapy with Pembrolizumab and Olaparib
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04753879
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Sep 29, 2021
Primary completion
May 7, 2026
Completion
Jul 1, 2026
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Dung Le, MD
principal investigator · SKCCC Johns Hopkins Medical Institution

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Olaparib

Start the discussion